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Abstract
Although catheter ablation is an effective treatment for recurrent atrial fibrillation (AF), there is no consensus on the definition of success 
or follow-up strategies. Symptoms are the major motivation for undergoing catheter ablation in patients with AF, however it is well known that 
reliance on perception of AF by patients after AF ablation results in an underestimation of recurrence of the arrhythmia. Because symptoms 
of AF occurrence may be misleading, a reliable assessment of rhythm outcome is essential for the definition of success in both clinical care 
and research trials. 
Continuous rhythm monitoring over long periods of time is superior to intermittent recording using external monitors to detect the 
presence of AF episodes and to quantify the AF burden. Today, new devices implanted subcutaneously using a minimally invasive technique 
have been developed for continuous AF monitoring. Implantable devices keep detailed information about arrhythmia recurrences and might 
allow identification of very brief episodes of AF, the significance of which is still uncertain. In particular, it is not known whether there is any 
critical value of daily AF burden that has a prognostic significance. This issue remains an area of active discussion, debate and investigation. 
Further investigation is required to determine if continuous AF monitoring with implantable devices is effective in reducing stroke risk and 
facilitating maintenance of sinus rhythm after AF ablation.
Introduction
Atrial fibrillation (AF) is one of the major common and chronic 
disorders seen in clinical practice1 and it is associated with a reduced 
quality of life and an increased long-term risk of stroke, heart failure 
and all cause mortality.2-3 A number of controlled, and randomized 
clinical trials have consistently shown that catheter ablation is 
superior to antiarrhythmic pharmacological treatment in maintaining 
sinus rhythm among patients with symptomatic drug-refractory 
AF.4-10 Remarkably there is no consensus on the definition of success 
or follow-up strategies after AF ablation. Even brief asymptomatic 
episodes can substantially raise the risk of stroke, therefore a reliable 
evaluation of AF recurrences is crucial after AF ablation and may be 
useful in making clinical decisions. 
Irrespective of symptoms, assessment of rhythm can be conducted 
with the use of intermittent (noninvasive) or continuous (implanted 
devices) monitoring systems. Increased duration of monitoring 
appears to be associated with increased rates of detection of AF and, 
on the basis of different monitoring techniques,11-12 sensitivity in 
detecting AF recurrences after catheter ablation is reported to range 
between 31% and 71% and negative predictive value between 21% 
and 65%.13
Non-Continuous Af Monitoring Systems
In addition to baseline ECG and symptom evaluation, several 
methods have been described to improve rhythm monitoring in AF 
patients. Intermittent monitoring includes periodical ECGs, Holter 
and event recorders with or without loop memory. The diagnostic 
accuracy of these methods is limited and it is well known that there 
is a clear relationship between the duration of monitoring and the 
diagnostic yield. 
Follow-up evaluation after AF ablation has been traditionally 
performed by routine ECG recordings and ambulatory 24-
hour Holter monitoring.14-16 Recently, new extended monitoring 
methods have been introduced, including trans-telephonic ECG 
transmissions, event recorders and external loop recorders. Systems 
without a loop memory allow intermittent rhythm monitoring and are 
useful to confirm recurrences in patients with symptoms suggestive 
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of those in the control arm [HR 7.3 (95% CI 2.6-20.8, p<0.0001)].
Implantable leadless device monitoring systems might override 
the problems related to the patient compliance and several data on 
continuous monitoring after AF ablation have recently been published. 
Verma et al. in a large multicentric prospective study evaluated the 
incidence of asymptomatic AF episodes before and after CA, as 
assessed by an implantable cardiac monitor with AF detection.24  In 
this study, ICM detected 12% of patients with purely asymptomatic 
AF and the ratio of asymptomatic to symptomatic AF episodes 
increase from 1.1 before to 3.7 after catheter ablation. Consistent 
with the results of this study, we have recently demonstrated in 145 
patients with paroxysmal or persistent AF, that continuous ECG 
monitoring is a valuable tool for long-term follow-up after AF 
catheter ablation facilitating reliable assessment of symptomatic and 
asymptomatic AF episodes.25 Furthermore, Bogachev-Prokophiev et 
al.26 confirmed the reliability of subcutaneous continuous monitoring 
also in patients who had undergone surgical AF ablation. 
Is Procedural Success Truly Achieved Without Continuous AF 
Monitoring?
The definition of “long-term ablation success” remains controversial. 
Guidelines state that the primary indication of AF ablation is 
to reduce AF-related symptoms and to improve quality of life. 
Secondary endpoints might include elimination of symptomatic AF 
and control of AF with previously ineffective antiarrhythmic drugs 
(AAD). The poor correlation between symptoms and AF27 should 
caution physicians against making clinical decisions depending on 
symptoms. Asymptomatic AF has been reported to be up to 12 times 
more frequent than symptomatic AF, even in patients with histories 
of symptomatic AF.28 Although ablation significantly reduces the 
burden of AF, the proportion of asymptomatic AF episodes increases, 
consequently the procedural success is overestimated by patient 
of AF. External loop recorder systems are ideal for capturing also 
asymptomatic AF recurrences; the ECG recording is triggered either 
automatically, according to the arrhythmia detection algorithm, 
or manually by the patient; besides device data can be stored on a 
memory card or sent through a telephone/internet connection. 
The main drawback of these systems is that they are tolerated only 
by highly motivated patients over a short period of time (usually few 
months). Thus, non-implantable recording systems play a limited role 
for a reliable and continuous monitoring of post-ablation recurrences. 
Furthermore, patients with infrequent AF recurrences are the 
most difficult to identify with intermittent monitoring and face a 
significant thromboembolic (TE) risk in the absence of appropriate 
oral anticoagulation (OAC) therapy. 
Continuous AF Monitoring Systems
Continuous AF monitoring can only be achieved through the 
diagnostics of implantable device, which can store significant 
information regarding heart rhythm. The first experience with 
continuous AF monitoring is derived from the analysis of data 
stored in dual-chamber pacemakers and implantable cardioverter-
defibrillators (ICD) capable of arrhythmia monitoring. If the atrial 
rate exceeds a programmable value for a given period of time, an 
atrial arrhythmia will be detected allowing the assessment of AF 
episodes irrespective of associated symptoms. 
The use of cardiac pacemaker as an implanted arrhythmia monitor 
has been first evaluated in the MOST trial.17 In a population of 312 
pacemaker patients, this study evaluated the correlation between the 
presence of atrial high rate events (AHRE) and clinical outcomes. The 
presence of AHRE longer than 5 min was found to be an independent 
predictor of total mortality and non-fatal stroke. Similarly, other large 
prospective multi-centric studies17-22 have examined the relationship 
between AF episodes detected by implanted devices and patient 
outcomes (Table 1). 
Dual-chamber pacemakers and implantable cardioverter-
defibrillators allow direct recording of atrial electrograms, but those 
devices are clearly not the ideal arrhythmia surveillance method, 
mainly because of the presence of intracardiac leads. To provide 
continuous information on cardiac rhythm, implantable leadless 
cardiac monitoring systems (ICM) with specific AF detection 
algorithms have been developed. Automatic triggers with physician-
programmable parameters allow AF episodes detection as well as 
AF burden quantification and batteries can last up to 5 to 6 years 
affording the possibility of prolonged continuous monitoring. The 
ICM memory can store both automatically detected AF episodes 
and a number of patient-activated episodes, which can be easily 
transmitted via telephone or internet to remotely and continuously 
evaluate a patient for AF recurrences after AF ablation.
The XPECT study13 evaluated for the first time the performance 
of an implantable leadless cardiac monitor (Reveal XT; Medtronic 
Inc.) with dedicated AF detection capabilities. The study showed 
that the overall accuracy of the ICM for detecting AF was 98.5% 
and the ICM-measured AF burden was very well correlated (Pearson 
coefficient r = 0.97) with the reference value derived from Holter. Very 
recently, the CRYSTAL-AF study23 demonstrated that this system is 
more effective than standard non-invasive monitoring methods to 
find an AF episode in patients with cryptogenic stroke. This study 
included 441 patients randomized to Reveal-XT or standard cardiac 
monitoring within 90 days of a cryptogenic stroke. At 12 months, 
AF was detected in 12.4% of patients in the Reveal arm versus 2.0% 
Table 1: Critical value of daily AT/AF burden: relationship with clinical 
events
Study, 
year
patients Detection 
Methods
Follow-
up
Endpoint AT/AF burden 
cutoff
 Hazard 
ratio and 
MOST 
2003
312 PM 27 
months
Total 
mortality
> 5 minutes HR 2.48
 P=0.0092
Death/non 
fatal stroke
> 5 minutes HR 2.79
P= 0.0011
Capucci 
et al.
2005
725 PM 22 
months
Arterial 
embolism
> 24 hours HR 3.1
p= 0.044
> 5 min P=NS
TRENDS  
2009
2486 PM/ICD 1.4 
years
Annualized 
TE rates
< 5.5 hours HR 0.98 
P= 0.97
> 5.5 hours HR 2.20 
P= 0.06
ASSERT 
2012
2580 PM/ICDor 
NSAIDs) 
or alcohol 
excess/
abuse
2.5 
years
Ischemic 
stroke/ 
systemic 
embolism
> 6 minutes HR 5.56
P<0.001
Clinical 
atrial 
fibrillation
> 6 minutes HR 5.56
P<0.001
SOS AF 
2013
10016 PM-ICD 24 
months
Ischaemic 
stroke
> 5 minutes HR 1.76 
P = 0.041
> 1 hour HR 2.11
P =.0.008
Abbreviations: AT/AF= atrial tachycardia/fibrillation; HR= Hazard Ratio; ICD= internal cardioverter 
defibrillator; PM= pacemaker; TE= thromboembolic..
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suggesting that TE events may also involve mechanisms other 
than cardioembolism due to atrial tachyarrhythmias. However, in 
this patient population short AF recurrences were very common, 
occurring in about 80% of patients; this might explain why device-
detected AF episodes < 5 min were not associated with a higher 
embolic risk. 
In a pooled analysis from three studies (TRENDS, PANORAMA 
and the Italian Clinical Service Registry), Boriani et al. assessed 
the association between the maximum daily AF burden and the 
risk of ischaemic stroke. This analysis on >10,000 patients without 
permanent AF 22 demonstrated that device-detected AF burden is an 
independent predictor of ischaemic stroke. Among the thresholds of 
AF burden evaluated, 1 h was associated with the highest hazard ratio 
(HR 2.11; P = 0.008) for ischaemic stroke. The threshold of ≥5 min 
was also statistically and significantly associated with the occurrence 
of ischaemic stroke, HR 1.76 (95% CI: 1.02–3.02, P . 0.041). 
Taken together these data from large cohorts of implanted patients 
add to the current evidence that measuring daily AF burden may 
have an important clinical relevance. New technologies of continuous 
rhythm monitoring might allow identification of very brief episodes 
of AF but is not known whether there is a critical value of daily AF 
burden that has a prognostic significance. The main issue is that AF is 
responsible for an increased risk of stroke and death, and elimination 
of AF normalises that risk; therefore great attention should be paid 
to device-detected AF episodes and treatment should be delivered 
accordingly. A comprehensive evaluation should combine AF burden 
and TE risk.18-20 Botto et al20 demonstrated that risk stratification 
for thromboembolic events in device-detected AF patients can be 
improved by combining CHADS2 score with AF presence and 
duration. 
Continuous AF Monitoring: Impacting Patient Outcomes
Atrial fibrillation ablation has the potential to restore sinus 
rhythm, eliminating the need for AADs and potentially for long-
term anticoagulation.27,46 Because AF symptoms may be misleading, 
appropriate rhythm monitoring surveillance after AF ablation may 
help to guide clinical decision making in certain subsets of patients. 
The present evidence suggests that a highly accurate follow-up, as 
provided by implantable devices, may add significant information to 
current clinical risk stratification schemes.42,47 The device-stored data 
can also be evaluated with remote monitoring systems, which can 
allow a prompt clinical reaction and may reduce hospitalizations and 
costs.
Optimal post-procedural anticoagulation strategy is essential for 
minimising bleeding and thromboembolic risk after AF ablation. 
Hemorrhagic risk can be lowered by reducing unnecessary and 
prolonged OAC administration while the patient is in sinus rhythm. 
In patients with CHADS score ≤2, OAC are frequently discontinued 
after AF ablation if no recurrences have been documented during 
follow-up. In a large reported experience on 831 patients after 
AF ablation , warfarin was stopped within 12 months in 76.5% of 
patients with no arrhythmia recurrence.14 This approach is commonly 
performed despite the fact that patients are frequently followed-
up with the use of limited temporal ECG monitoring duration. 
However, caution should be considered before OAC withdrawal 
because unrecognized recurrences might lead to devastating 
consequences, including death and thromboembolic stroke. If OAC 
are discontinued after AF ablation, the risk of asymptomatic AF 
recurrences cannot be ruled out without a continuous AF monitoring 
symptoms11 Silent AF is likely to be associated with morbidity and 
mortality rates not inferior to symptomatic AF,21,29-30 therefore, a 
reliable rhythm outcome analysis after AF ablation has the potential 
to reduce that risk. Post-procedure arrhythmia monitoring is also 
useful because in a significant number of patients, palpitations may 
be misinterpreted as AF episodes; in one study , 40% of pacemaker 
patients reported symptoms suggestive of AF that were not confirmed 
neither by standard ECG recording nor device interrogation.31
Emerging evidence suggests that sinus rhythm restoration following 
AF ablation can provide clinical and prognostic benefits.32-38 Winkle 
et al39 have recently demonstrated that patients with prior stroke, who 
under successful AF ablation, have a low incidence of subsequent 
thromboembolic events, and most of those patients may be able to 
discontinue OAC. The consistency of these findings suggests that 
restoration of sinus rhythm by catheter ablation might result in 
lower rates of stroke and death. Of note, the Heart Rhythm Society’s 
consensus document on AF ablation recommends that success can 
be defined as freedom from AF or atrial tachycardia, lasting 30 
seconds 12 months after AF ablation.40 Intermittent and symptom-
based monitoring is highly inaccurate for identifying patients with 
AF recurrences41,42 leaving untreated a vulnerable population. Thus, 
implantable devices are the most reliable method to precisely identify 
AF recurrences after AF ablation both in clinical care and in the 
setting of a clinical research study.
Estimating AF Burden: The Importance Of Cutoff Length
The unexpectedly high incidence of ICM-detected non-sustained 
atrial arrhythmias raises the question of whether there is any 
clinical significance to these, often asymptomatic, AF episodes. 
Quantitative AT/AF burden detected by implanted devices may 
be a thromboembolic (TE) risk element independent of standard 
stroke risk factors and absence of symptoms can even increase the 
thromboembolic risk if objective information on AF status is lacking.
Current guidelines do not specifically address any anticoagulation 
use in case of non-sustained device-detected AF episodes. Generally, it 
has been demonstrated that patients with AHREs, compared to those 
without AHREs, are more likely to have adverse clinical outcomes, 
including a higher incidence of stroke, death and subsequent AF. 
The adverse effects of paroxysmal AF have been correlated to the 
duration of the episodes and to the AF burden (Table 1).  However, 
the amount of AF burden that conveys a substantial risk of stroke has 
been the object of debate. In particular, it is not clear whether very 
brief AF episodes are associated with a significant risk of stroke and 
deserve OAC therapy.
The ASSERT trial21 suggests that subclinical atrial high-rate 
episodes (>190 bpm lasting more than 6 minutes) conferred a relative 
risk of 2.49 (p=0.007) for subsequent ischemic stroke or systemic 
embolism. These data strongly suggest that, if available, AHRE data 
should be collected and used to risk-stratify pacemaker patients. 
Other studies showed that even shorter AF episodes lasting < 30 
seconds might be associated with the presence of stroke or TIA.17, 43,44 
The relationship between the AF burden and stroke risk is uncertain 
and still an area of active investigation. Capucci et al, in a population 
of 788 pacemaker patients suffering from AF, demonstrated that only 
device-detected AF episodes lasting > 24 hours were independently 
associated with embolic events while shorter episodes (> 5min) 
did not increased the TE risk.18  Furthermore, in a subanalysis of 
the TRENDS study,45 the majority of thromboembolic events did 
not occur proximal to recent device-detected AT/AF episodes, 
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system.
The routine use of cardiac monitoring to identify AF patients 
who will benefit from anticoagulation has been reported to be cost-
effective.48 Continuous AF monitoring with implanted devices 
increases sensitivity of AF detection when compared to conventional 
diagnostic methods20 and data transmission allows a remote and 
continuous evaluation for AF recurrences. Recently, the ANGELS 
of AF project demonstrated the possibility to improve OAC use as 
thrombo-prophylaxis through the use of information from ICD AF-
diagnostics as compared with standard care.49
Early diagnosis triggers earlier treatment and in this regard novel 
OAC (dabigratan, rivaroxaban and apixaban), which might be early 
self-administered without dose titration, allows for rapid onset 
anticoagulation with a single oral dose early after an AF episode. 
Current evidence suggests that a prothrombotic state is evident 
within minutes after the onset of an AF episode.50-51 Since left atrial 
thrombi can develop early during AF episodes, an early AF detection 
afforded by ICM might increase the safety of discontinuing OAC 
after AF ablation. The ongoing IMPACT trial52 has been designed to 
test the hypothesis that initiation or withdrawal of oral anticoagulant 
therapy guided by continuous ambulatory monitoring of the atrial 
intracardiac electrograms improves clinical outcomes. This study has 
the potential to provide some answers to this important question but 
it has been stopped early and remains unpublished.
Beyond implementation of appropriate anticoagulation, an early 
intervention following device-detected AF episodes has other 
potential benefits in improving the management of patients after 
AF ablation. It is likely that the benefits of sinus rhythm are in part 
counterbalanced by the potential adverse effects of long-term AAD 
use.53 The detailed rhythm information obtained through continuous 
monitoring might allow an earlier AAD discontinuation reducing 
the potential side effects of medications.
Brief and predominantly asymptomatic AF episodes may remain 
undetected until the next scheduled evaluation delaying the 
appropriate management of AF recurrences. Early diagnosis, through 
continuous AF monitoring, triggers earlier treatment and might also 
facilitate the self-administration of a single oral dose of Ic drug (pill-
in-the-pocket)54 shortly after the onset of the AF recurrence.  The 
prolonged duration of AF negatively effects electrical and structural 
atrial remodelling, therefore early restoration of sinus rhythm might 
have potential benefits over the long-term follow-up.
Optimal Time And Duration Of AF Monitoring
Limited data are available on the optimal time and duration of 
monitoring after AF ablation. Continuous AF monitoring might 
be useful both in the short-term and over the long-term follow-up 
after AF ablation. Early recurrences of AF are quite common in the 
so-called blanking period and are often asymptomatic.55 However, 
appropriate surveillance during the early post-ablation period may 
identify patients who are at a higher risk of long term treatment 
failure since early recurrences strongly predict a lack of long-term 
success.56-57
Pokushalov et al. demonstrated in 286 patients continuously 
monitored through an implantable device after AF ablation, that this 
strategy might be useful for deciding whether to perform a second 
ablation or to implement drug therapy.20 In this study patients 
were treated according to the onset mechanism of AF recurrences, 
as detected and stored by the implantable cardiac monitor. They 
observed that patients with recurrences after the first AF ablation are 
likely to respond to a second early ablation when AF is triggered by 
supraventricular arrhythmias or premature contractions.
Several clinical studies assessing the long-term efficacy of catheter 
ablation procedures have reported late AF recurrences in patients 
who were initially considered responders to catheter ablation.58 
Therefore, longer-term monitoring might identify AF episodes 
in patients in whom the OAC had been previously suspended. 
Because of the recognition of the late AF recurrences, the HRS/
EHRA/ECAS consensus document on AF ablation concluded that 
a decision regarding OAC discontinuation should be based on the 
CHADS stroke risk score rather than the apparent efficacy of the 
AF ablation procedure.
False Positive Device-Detected Events
Long-term AF monitoring by implanted devices may be of 
substantial clinical value. However, its practical application may, 
in part, be limited by the prevalence of false-positive events. The 
risk of false-positives detections mainly generated by myopotential 
and motion artefacts still exists,13,48 highlighting the importance 
of human revaluation of automatically detected episode. False-
positive events might lead to unscheduled evaluations in patients 
with remote follow-up that significantly increase the physician work 
burden.59,60 Unscheduled patient evaluation after ICM implantation 
has also a major impact on quality of life and cost-effectiveness in 
ICM recipients. Longer cutoff might result in a reduced number of 
false-positive events. An analysis from the ASSERT trial by using 
a cutoff of >6 minutes and >190 beats/min showed a 17.3% rate 
of false-positive AHREs, making physician review of electrograms 
essential.61 For AHREs lasting >6 hours, the rate of false positives is 
3.3%, making physician review less crucial.
New sensing and detection algorithms for ICM have been developed 
in order to substantially reduce the occurrence of inappropriately 
detected AT/AF episodes.62 A higher specificity of the algorithm is 
necessary and would avoid unnecessary clinical evaluations once the 
alert system is activated. Future research will focus on optimal device 
programming that will offer maximal benefit, increasing the clinical 
utility of ICM algorithms.
Conclusions:
Because AF symptoms may be misleading, appropriate rhythm 
monitoring surveillance after AF ablation may help to guide clinical 
decision making in certain subsets of patients. The present evidence 
suggests that a highly accurate follow-up, as provided by implantable 
devices, may add significant information to current clinical risk 
stratification schemes.
Implantable devices keep detailed information about arrhythmia 
recurrences and might allow identification of very brief episodes 
of AF, the significance of which is still uncertain. In particular, it is 
not known whether there is a critical value of daily AF burden that 
has any prognostic significance. This issue remains an area of active 
discussion, debate and investigation. Further investigation is required 
to determine if continuous AF monitoring with implantable devices 
is effective in reducing stroke risk and facilitating maintenance of 
sinus rhythm after AF ablation.
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